RGX-121-3102 gene therapy

· REGENXBIO Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RGX-121-3102 gene therapy, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) [Phase 3]